Literature DB >> 9373974

Basic characteristics of distortion product otoacoustic emissions in infants and children.

B A Prieve1, T S Fitzgerald, L E Schulte, D T Kemp.   

Abstract

Distortion-product otoacoustic emissions at the 2 f1-f2 frequency (DPOAEs) are being advocated as a clinical tool for diagnosis of peripheral auditory pathology. Because they can be measured quickly and noninvasively, they may be an excellent method for identifying hearing loss in infants and children. However, few studies have examined the characteristics of DPOAEs in infants and children or detailed if, and how, their responses differ from those of adults. The purpose of the current study was to determine basic characteristics of DPOAEs in infants, toddlers, children, and young adults and to define any differences among age groups. An additional goal was to ensure that the presence of spontaneous otoacoustic emissions (SOAEs) did not confound any developmental effect. DPOAE input/output (I/O) functions at seven f2 frequencies and SOAEs were measured from one ear of 196 subjects. Children aged less than 1 yr had significantly higher mean DPOAE levels than older children and adults, and children aged 1-3 yr had higher mean DPOAE levels than teens and adults. These differences were dependent on frequency but were independent of f2 level and SOAE status. At every f2 frequency, groups of individuals having SOAEs had higher mean DPOAE levels than those not having SOAEs.

Entities:  

Mesh:

Year:  1997        PMID: 9373974     DOI: 10.1121/1.420342

Source DB:  PubMed          Journal:  J Acoust Soc Am        ISSN: 0001-4966            Impact factor:   1.840


  10 in total

1.  [Universal neonatal screening as an application of automated audiological techniques].

Authors:  W Delb
Journal:  HNO       Date:  2003-12       Impact factor: 1.284

2.  [The influence of conductive hearing loss on DPOAE-threshold. The effect of an individually optimized stimulation].

Authors:  P Kummer; E M Schuster; F Rosanowski; U Eysholdt; J Lohscheller
Journal:  HNO       Date:  2006-06       Impact factor: 1.284

3.  Assessment: scientific foundation.

Authors:  R J Nozza
Journal:  Trends Amplif       Date:  1999-06

4.  Longitudinal Development of Distortion Product Otoacoustic Emissions in Infants With Normal Hearing.

Authors:  Lisa L Hunter; Chelsea M Blankenship; Douglas H Keefe; M Patrick Feeney; David K Brown; Annie McCune; Denis F Fitzpatrick; Li Lin
Journal:  Ear Hear       Date:  2018 Sep/Oct       Impact factor: 3.570

5.  Optimizing Clinical Interpretation of Distortion Product Otoacoustic Emissions in Infants.

Authors:  Chelsea M Blankenship; Lisa L Hunter; Douglas H Keefe; M Patrick Feeney; David K Brown; Annie McCune; Denis F Fitzpatrick; Li Lin
Journal:  Ear Hear       Date:  2018 Nov/Dec       Impact factor: 3.570

6.  Long-Term Variability of Distortion-Product Otoacoustic Emissions in Infants and Children and Its Relation to Pediatric Ototoxicity Monitoring.

Authors:  Dawn Konrad-Martin; Kristin Knight; Garnett P McMillan; Laura E Dreisbach; Elsa Nelson; Marilyn Dille
Journal:  Ear Hear       Date:  2020 Mar/Apr       Impact factor: 3.570

7.  Changes in the DP-gram during the preterm and early postnatal period.

Authors:  Carolina Abdala; Sandra I Oba; Rangasamy Ramanathan
Journal:  Ear Hear       Date:  2008-08       Impact factor: 3.570

8.  Using benefit-cost ratio to select Universal Newborn Hearing Screening test criteria.

Authors:  Heather L Porter; Stephen T Neely; Michael P Gorga
Journal:  Ear Hear       Date:  2009-08       Impact factor: 3.570

9.  Distortion Product Otoacoustic Emissions: A Tool for Hearing Assessment and Scientific Study.

Authors:  Caroline Abdala; Leslie Visser-Dumont
Journal:  Volta Rev       Date:  2001

10.  Otoacoustic emissions from ears with spontaneous activity behave differently to those without: Stronger responses to tone bursts as well as to clicks.

Authors:  W Wiktor Jedrzejczak; Krzysztof Kochanek; Henryk Skarzynski
Journal:  PLoS One       Date:  2018-02-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.